Compounding lobby group sues FDA over semaglutide shortage list removal, arguing Novo Nordisk's Ozempic and Wegovy remain in ...

Emalex Biosciences said its daily oral tablet helped reduce relapses for children and adults with Tourette syndrome in a ...

An Illinois jury ruled in favor of Boehringer Ingelheim in Zantac litigation brought by two prostate cancer patients, the ...

Eli Lilly is buying Organovo’s farnesoid X receptor (FXR) agonist program, which includes a drug in Phase 2 development for ...

Hims & Hers expects revenue from its weight loss business to soar in 2025, even though a recent FDA move could make it ...

Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean ...

Thermo Fisher Scientific is spending $4.1 billion in cash to acquire US healthcare company Solventum’s purification and ...

Eli Lilly will start selling additional single-dose vials of its weight loss drug Zepbound at a lower price for certain ...

Takeda must have liked what it got from the chemoproteomics work out of BridGene Biosciences. The Tokyo-based drugmaker ...

For the fourth year running, Endpoints News will highlight the biotech leaders who are paving the way for the LGBTQ+ ...

Alnylam may be gearing up for its biggest commercial launch yet in its nearly 23-year history, but the company’s top ...

FDA ends semaglutide shortage, impacting compounding pharmacies. Hims & Hers plans personalized versions while Olympia ...